tiprankstipranks
Ocular Therapeutix (OCUL)
NASDAQ:OCUL
US Market
OCUL
Ocular Therapeutix
RESEARCH TOOLSreports

Ocular Therapeutix (OCUL) Stock News & Sentiment

1,583 Followers
OCUL: SOL-1 Phase 3 Data, Regulatory Strategy, and Durability Advantages Underpin Reaffirmed Buy Rating and $27 Target
Premium
Ratings
OCUL: SOL-1 Phase 3 Data, Regulatory Strategy, and Durability Advantages Underpin Reaffirmed Buy Rating and $27 Target
1M ago
OCUL
Axpaxli’s Superior SOL-1 Phase 3 Data Support Buy Rating and Constructive Outlook on Ocular Therapeutix
Premium
Ratings
Axpaxli’s Superior SOL-1 Phase 3 Data Support Buy Rating and Constructive Outlook on Ocular Therapeutix
1M ago
OCUL
OCUL: Strengthening Axpaxli Clinical Profile and Manageable Safety Support Buy Rating in Neovascular AMD
Premium
Ratings
OCUL: Strengthening Axpaxli Clinical Profile and Manageable Safety Support Buy Rating in Neovascular AMD
1M ago
OCUL
Ocular Therapeutix Highlights Phase 3 AXPAXLI Trial Progress
Premium
Company Announcements
Ocular Therapeutix Highlights Phase 3 AXPAXLI Trial Progress
1M ago
8K
OCUL
Ocular Therapeutix: SOL-1 Data Validate Axpaxli and Overdone Sell-Off Supports Buy Rating
Premium
Ratings
Ocular Therapeutix: SOL-1 Data Validate Axpaxli and Overdone Sell-Off Supports Buy Rating
1M ago
OCUL
Regulatory Turbulence Threatens Ocular Therapeutix: FDA Disruptions and Global Delays Raise Approval and Funding Risks
Premium
Company Announcements
Regulatory Turbulence Threatens Ocular Therapeutix: FDA Disruptions and Global Delays Raise Approval and Funding Risks
2M ago
OCUL
Ocular Therapeutix appoints Jason Robins interim CFO
Premium
Company Announcements
Ocular Therapeutix appoints Jason Robins interim CFO
2M ago
8K
OCUL
More OCUL News >

OCUL News on the Web

Ocular Therapeutix to Unveil New SOL-1 Phase 3 Data on AXPAXLI for Wet AMD at April Conferences
Market Chameleon
Neutral
Analysts Have Conflicting Sentiments on These Healthcare Companies: AbbVie (ABBV), Molina Healthcare (MOH) and Ocular Therapeutix (OCUL)
TipRanks News
Bullish
Analysts Offer Insights on Healthcare Companies: Ocular Therapeutix (OCUL) and Rhythm Pharmaceuticals (RYTM)
TipRanks News
Neutral
Ocular Therapeutix Inc at RBC Capital Markets Ophthalmology Conference (Virtual) Transcript
GuruFocus News
Neutral
Relay Therapeutics (RLAY) Soars 5.4%: Is Further Upside Left in the Stock?
Zacks
Neutral
Ocular Therapeutix price target raised to $27 from $24 at BofA
TipRanks News
Neutral
OCUL: SOL-1 Phase 3 Data, Regulatory Strategy, and Durability Advantages Underpin Reaffirmed Buy Rating and $27 Target
TipRanks News
Bullish
Ocular Therapeutix (OCUL): Analyst Raises Price Target Amid Steady Buy Rating | OCUL Stock News
GuruFocus News
Bullish

News Score - Last 7 Days

Neutral
OCUL
Sector Average
Media Buzz
This Week3 articles
Weekly Average1.25 articles
News Sentiment
This Week100%
Sector Average65%
See how Bullish or Bearish a stock is based on its recent media coverage.

This score is generated using a formula that combines Media Buzz and News Sentiment.

Media Coverage Analysis

The historical news coverage of this asset in the last three months.

FAQ

What is OCUL’s Media Buzz Sentiment?
3 articles about OCUL were published this week. In an average week, 1.25 articles are published.
    What is OCUL’s weekly average amount of articles?
    In an average week, 1.25 articles about OCUL are published.
      What is OCUL’s News Sentiment?
      100% of articles about OCUL were positive this week, compared to its sector average of 65%.
        Healthcare Stocks that are Trending in the News
        PALIPalisade Bio
        6699Angelalign Technology Inc.
        KODKodiak Sciences
        OMEROmeros
        640China Resources Pharmaceutical Group Ltd.
        Showing the stocks with the most bullish news sentiment over the past week